Hospitals May Be Slow To Add Vitamin D To COVID-19 Treatment Regimens Because Of Loss Of Income
Hospitals May Be Slow To Add Vitamin D To COVID-19 Treatment Regimens Because Of Loss Of Income By Bill Sardi for Lew Rockwell
A growing body of published studies indicate vitamin D supplementation may allay the symptoms and severity of COVID-19 infections, enough to keep hospitalized patients out of the intensive care unit. The most recent of these studies, published in The Journal of Steroid Biochemistry and Molecular Biology (Aug 29,2020) is more than convincing.
But this remarkable study is not likely to change the practices of modern medicine, even though it completely abolished COVID-19-related deaths in the intensive care unit (ICU) and reduced admission from a standard COVID-19 care ward to the ICU from 50% to 2%.
The study involved 76 hospitalized patients who were COVID-19-positive and had symptoms of coronavirus infection such as dry cough, shortness of breath, fever and diarrhea who were on a standard-care COVID-19 hospital ward.
Critics say the study is not large enough, co-morbid conditions such as obesity, diabetes and autoimmunity were grouped rather than identified specifically, and there were no vitamin D blood levels taken before and after treatment. Yet there were no adverse reactions. So, what harm could come from a hospital giving vitamin D to all patients on its COVID-19 ward?
THE CONVINCING DATA
The following chart reveals just 2% of COVID-19 COVID-19-infected patients given VITAMIN D25 (as prescription-only calcifediol (cal-siff-i-die-ol), needed to be transferred to the ICU (intensive care unit) from a standard care ward whereas 50% of those COVID-19 infected patients NOT given vitamin D worsened to the point where intensive care and ventilator support was required.
Non-prescription vitamin D3 (cholecalciferol) is converted to vitamin D25 calcifediol in the liver. Therefore Rx-only calcifediol works faster than non-Rx vitamin D3.
Vitamin D inhibits newly recognized cause of COVID-19 death
Vitamin D is known to inhibit the buildup of bradykinin (bray-dih-kî-nin), a natural internally-produced blood vessel dilator which helps control blood pressure. Excessive bradykinin can induce contraction of the bronchus, an airway to the lungs, thus impairing breathing.